Abstract
This study aimed to evaluate the efficacy of combined treatment with recombinant interleukin-2 (rIL-2) and allicin on pancreatic cancer and explore the potential immunological mechanism. A total of 60 C57/BL6 nude mice pancreatic cancer xenograft models were randomized into four groups of 15 mice per group: control group, allicin treatment group, rIL-2 treatment group, combined treatment with allicin and rIL-2 group. Mice in each group were treated with saline, rIL-2, allicin, or combination of rIL-2 and allicin by weekly i.v injection for four weeks. After four weeks of treatment, eyeballs of the mice were extracted and blood was drawn, percentages of CD4+T, CD8+T and NK cell were analyzed by FACS, IFN-γ level was detected by ELISA. One mouse in each group was sacrificed to measure the weight and volume of the tumor and prepared to the paraffin section of tumor tissue. Apoptosis of the tumor cells was analyzed by TUNEL and FACS. Other mice continued to receive treatment, survival period were compared between each group. We observed a significant suppression of xenograft growth and a significant prolonged survival time in the combined treatment with allicin and rIL-2 group (P < 0.05). The most amount of apoptotic cells were observed in the combined therapy group (P < 0.05). The percentages of CD4+T, CD8+T and NK cell and serum IFN-γ level increased significantly in the combined treatment group compared with other groups (P < 0.05). Combined treatment with allicin and rIL-2 resulted in suppression of tumor growth and prolonged survival time possibly through activation of CD4+T, CD8+T and NK cell.
Similar content being viewed by others
References
Fleischauer AT, Arab L (2001) Garlic and cancer: a critical review of the epidemiologic literature. J Nutr 131(3):1032s–1040s
Lamm DL, Riggs DR (2001) Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. J Nutr 131(3):1067s–1070s
Ghazanfari T, Hassan ZM, Ebtekar M, Ahmadiani A, Naderi G, Azar A (2000) Garlic induces a shift in cytokine pattern in Leishmania major-infected BALB/c mice. Scand J Immunol 52(5):491–495
Leong KH, Ramshaw IA, Ramsay AJ (1997) Interleukin-7 enhances cell-mediated immune responses in vivo in an interleukin-2-dependent manner. Viral Immunol 10(1):1–9
Watson J, Mochizuki D (1980) Interleukin 2: a class of T cell growth factors. Immunol Rev 51:257–278
Bleackley RC, Barr PJ, Havele C, Hooton J, Ng J, Meier M, Merryweather JP, Gibbs C, Paetkau V (1985) Biologic activities of recombinant human interleukin-2 on murine lymphocytes. Lymphokine Res 4(2):117–131
Bosetti C, Bertuccio P, Negri E, La Vecchia C, Zeegers MP, Boffetta P (2012) Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog 51(1):3–13. doi:10.1002/Mc.20785
Rozen P, Liphshitz I, Rosner G, Barchana M, Lachter J, Pel S, Shohat T, Santo E, Consortium IPC (2009) Pancreatic cancer in Israel: the epidemiology, possibilities of prevention, early detection and screening. Isr Med Assoc J 11(12):710–713
Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Thun MJ (2009) Cancer Statistics, 2009. CA Cancer J Clin 59(4):225–249. doi:10.3322/Caac.20006
Kleeff J, Michalski C, Friess H, Buchler MW (2006) Pancreatic cancer - From bench to 5-year survival. Pancreas 33(2):111–118
Brasiuniene B, Juozaityte E (2007) The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer. Medicina-Lithuania 43(9):716–725
von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B, Kalthoff H (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7(3):925s–932s
Plate JMD, Harris JE (2000) Immune cell functions in pancreatic cancer. Crit Rev Immunol 20(5):375–392
Koido S, Homma S, Hara E, Namiki Y, Takahara A, Komita H, Nagasaki E, Ito M, Ohkusa T, Gong J, Tajiri H (2010) Regulation of tumor immunity by tumor/dendritic cell fusions. Clin Dev Immunol 2010:516768
Koido S, Homma S, Hara E, Namiki Y, Takahara A, Komita H, Nagasaki E, Ito M, Ohkusa T, Gong J, Tajiri H (2010) Regulation of tumor immunity by tumor/dendritic cell fusions. Clin Dev Immunol 2010:516768. doi:10.1155/2010/516768
Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC (2010) Regulatory T cells in cancer. Adv Cancer Res 107:57–117. doi:10.1016/S0065-230X(10)07003-X
Shevach EM (2009) Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30(5):636–645. doi:10.1016/j.immuni.2009.04.010
Singh SV, Powolny AA, Stan SD, Xiao D, Arlotti JA, Warin R, Hahm ER, Marynowski SW, Bommareddy A, Potter DM, Dhir R (2008) Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice. Cancer Res 68(22):9503–9511. doi:10.1158/0008-5472.Can-08-1677
Sun L, Wang X (2003) Effects of allicin on both telomerase activity and apoptosis in gastric cancer SGC-7901 cells. World J Gastroenterol 9(9):1930–1934
Xiao D, Lew KL, Kim YA, Zeng Y, Hahm ER, Dhir R, Singh SV (2006) Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction. Clin Cancer Res 12(22):6836–6843. doi:10.1158/1078-0432.Ccr-06-1273
Ishikawa H, Saeki T, Otani T, Suzuki T, Shimozuma K, Nishino H, Fukuda S, Morimoto K (2006) Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. J Nutr 136(3):816s–820s
Lake RA, Robinson BWS (2005) Immunotherapy and chemotherapy—a practical partnership. Nat Rev Cancer 5(5):397–405. doi:10.1038/Nrc1613
Degrate L, Nobili C, Franciosi C, Caprotti R, Brivio F, Romano F, Leone BE, Trezzi R, Uggeri F (2009) Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg 394(1):115–121. doi:10.1007/s00423-008-0393-4
Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM (2000) In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 97(6):2731–2736
Butt MS, Sultan MT, Butt MS, Iqbal J (2009) Garlic: nature’s protection against physiological threats. Crit Rev Food Sci Nutr 49(6):538–551. doi:10.1080/10408390802145344
Patya M, Zahalka MA, Vanichkin A, Rabinkov A, Miron T, Mirelman D, Wilchek M, Lander HM, Novogrodsky A (2004) Allicin stimulates lymphocytes and elicits an antitumor effect: a possible role of p21ras. Int Immunol 16(2):275–281. doi:10.1093/intimm/dxh038
Tang X-l Jz-y, Cai S-y (2008) Enhanced effect of CD8+T cells activated by tumor lysate-pulsed DCs on killing autologous tumor cells. Chinese J Pathophysiol 1000–4718
Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT (2009) Pharmacologic administration of interleukin-2. Ann N Y Acad Sci 1182:14–27. doi:10.1111/j.1749-6632.2009.05160.x
Krastev Z, Koltchakov V, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Koten JW, Jacobs J, Den Otter W (2005) Locoregional IL-2 low dose applications for gastrointestinal tumors. World J Gastroenterol 11(35):5525–5529
Duluc D, Tan F, Scotet M, Blanchard S, Fremaux I, Garo E, Horvat B, Eid P, Delneste Y, Jeannin P (2009) PolyI:C plus IL-2 or IL-12 induce IFN-gamma production by human NK cells via autocrine IFN-beta. Eur J Immunol 39(10):2877–2884. doi:10.1002/eji.200838610
Wulff S, Pries R, Wollenberg B (2010) Cytokine release of human NK cells solely triggered with Poly I:C. Cell Immunol 263(2):135–137. doi:10.1016/j.cellimm.2010.03.020
Acknowledgments
This project is supported by Grants from the National Natural Science Foundation of China (No.30872510; 81200320; 81272534 and 81260349) the Natural Science Foundation of Hubei Province (No. 2008CDB127), and the Natural Science Foundation of Shanghai (No. 064119620 10411968400).
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical standards
All human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. All persons gave their informed consent prior to their inclusion in the study.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Cong-Jun Wang and Jiang Han are co-first authors.
Rights and permissions
About this article
Cite this article
Wang, CJ., Wang, C., Han, J. et al. Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer. Mol Biol Rep 40, 6579–6585 (2013). https://doi.org/10.1007/s11033-013-2766-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-013-2766-1